Table-S1. Mean absorbance values obtained by in-house IgG ELISA for detection of IgG, and IgG1, IgG2, IgG3 and IgG4 antibody isotypes in samples (serum/plasma) collected from 85 no-hospitalized COVID-19 convalescent subjects

	ID	Specimen	Time (days) RT-qPCR & Sample	ELISA IgG >0.312	ELISA IgG1 >0.242	ELISA IgG2 >0.186	ELISA IgG3 >0.375	ELISA IgG4 >0.251
1	BBMC102	Serum	Unknown	2.5619	2.59	0.172	0.78	0.119
2	BBMC103	Serum	Unknown	2.5235	1.91	-0.02	0.56	0.023
3	BBMC104	Serum	Unknown	0.9734	0.26	0.036	0.09	0.078
4	BBMC105	Serum	35	2.4548	3.7	0.108	1.315	0.15
5	BBMC106	Serum	35	0.8364	0.14	0.133	0.04	0.088
6	BBMC132	Serum	32	2.1755	3.01	0.005	0.37	0.099
7	BBMC133	Serum	37	1.0806	0.01	0.037	0.06	0.036
8	BBMC134	Serum	32	0.822	0.23	0.166	0.02	0.15
9	BBMC135	Serum	37	1.98	0.31	0.179	0.185	-0.14
10	BBMC136	Serum	38	0.045	0.05	0.09	0.1	0.08
11	BBMC137	Serum	34	1.037	0.12	-0.018	0.04	0.006
12	HAM143	Serum	1	2.851	3.156	0.003	2.282	0.029
13	BBMC148	Serum	39	2.25	0.684	0.133	0.32	0.004
14	LMH151	Serum	48	2.189	1.097	1.383	1.037	0.092
15	BSCM152	Serum	45	1.194	0.166	-0.246	0.398	0.009
16	LML153	Serum	48	2.26	1.958	-0.23	0.747	0.057
17	BBSM155	Plasma	20	1.371	0.58	0.023	0.18	1.22
18	BBSM156	Plasma	47	1.759	0.515	0.229	0.060	0.120
19	BBSM157	Plasma	27	2.483	0.6	0.154	0.3	0.111
20	BBSM158	Plasma	20	3.207	2.5	0.088	0.45	0.164
21	BBSM159	Plasma	26	3.056	2.81	0.063	0.57	0.355
22	BBSM160	Plasma	31	1.897	0.412	0.027	0.006	0.056
23	BBSM161	Plasma	22	2.958	1.75	0.079	0.6	0.07
24	BBSM162	Plasma	48	2.122	0.48	-0.038	0.320	0.085
25	BBSM163	Plasma	27	1.437	0.575	-0.055	0.090	0.230
26	BBSM164	Plasma	29	2.603	1.26	0.051	0.3	0.26
27	BBSM165	Plasma	30	2.196	0.325	0.027	0.05	0.13
28	BBSM166	Plasma	44	1.783	0.175	-0.045	0.142	0.114
29	BBSM167	Plasma	22	1.798	0.556	0.051	0.04	0.035
30	BBSM170	Plasma	48	3.140	1.61	0.036	0.175	0.315
31	BBSM171	Plasma	41	2.477	0.41	-0.034	0.185	0.300
32	BBSM173	Plasma	33	3.204	0.97	0.047	0.48	0.025
33	BBSM176	Plasma	42	2.512	0.45	-0.041	0.550	0.028
34	BBSM177	Plasma	36	2.200	0.2	-0.058	0.13	0.05
35	BBSM178	Plasma	36	1.571	0.165	0.057	0.24	0.055
36	BBSM179	Plasma	14	1.265	0.01	-0.056	0.079	0.090
37	BBSM180	Plasma	13	2.052	0.05	-0.051	0.041	0.015
38	BBSM181	Plasma	48	1.715	0.06	-0.036	0.055	0.006
39	BBSM182	Plasma	38	2.906	0.36	-0.031	0.15	0.02
40	BBSM184	Plasma	37	1.752	0.77	-0.057	0.13	-0.01
41	LCTC192	Serum	Unknown	0.977	0.032	-0.047	0.057	-0.056
42	BBMC193	Plasma	54	2.539	1.101	0.017	0.023	0.026
43	BBMC195	Plasma	61	3.329	1.06	-0.007	0.256	0.246
44	BBSM199	Serum	61	1.464	0.086	0.037	0.023	-0.073
45	BBSM201	Serum	29	0.544	0.054	0.047	0.079	-0.088
46	BBSM207	Plasma	54	2.576	0.389	0.0509	0.129	-0.049
47	BBSM209	Plasma	34	2.474	0.297	0.005	0.062	0.043
48	BBSM210	Plasma	18	3.053	0.732	0.180	0.033	0.024
49	BBSM214	Plasma	96	3.483	2.695	0.112	2.710	-0.006
50	LCTC218	Serum	Unknown	1.253	-0.09	0.060	0.057	-0.018
51	BBMC220	Plasma	69	3.326	2.047	0.012	1.12	0.018
52	BBSM229	Plasma	35	2.103	0.380	0.216	0.125	0.000
53	BBSM231	Plasma	28	2.33	0.513	0.034	0.150	0.072
54	UPR247	Serum	Unknown	0.448	-0.172	0.012	-0.009	0.0124
55	LV260	Plasma	0	2.750	1.054	0.213	0.185	0.183

56	LV261	Serum	0	3.185	2.652	0.098	2.125	-0.006
57	LV262	Serum	0	2.655	0.689	-0.219	0.13	0.112
58	BBSM275	Plasma	84	3.534	1.177	0.074	0.045	0.253
59	BBSM284	Plasma	84	3.205	0.935	-0.013	0.147	-0.065
60	BSSM288	Plasma	116	1.948	0.275	0.103	0.051	0.126
61	LCTC300	Serum	25	0.802	-0.006	0.123	0.006	0.119
62	LCTC312	Plasma	14	2.755	0.496	0.056	0.121	0.038
63	BBSM318	Plasma	15	3.205	1.631	0.050	0.189	-0.079
64	BBSM322	Plasma	33	3.500	2.09	0.469	0.312	0.014
65	LCTC367	Plasma	Unknown	2.578	1.514	0.090	0.509	0.328
66	LCTC374	Serum	Unknown	1.1012	0.129	0.062	0.528	0.106
67	LCTC375	Serum	Unknown	2.938	2.049	0.053	0.360	0.524
68	LCTC376	Serum	Unknown	2.6602	0.646	-0.016	0.031	0.054
69	LCTC377	Serum	Unknown	1.207	-0.029	0.035	-0.054	0.212
70	UPR381	Serum	36	2.149	0.834	3.166	1.514	0.029
71	UPR382	Plasma	Unknown	1.51	0.567	0.086	0.064	0.211
72	LCTC384	Serum	Unknown	1.805	0.710	0.014	0.537	-0.033
73	BBSM386	Plasma	42	1.226	0.033	0.048	-0.035	0.069
74	BBSM390	Plasma	26	1.876	0.503	0.018	0.587	0.128
75	BBSM391	Plasma	68	2.409	1.499	-0.010	0.124	-0.067
76	BBSM393	Plasma	25	0.624	0.05565	-0.002	0.040	-0.077
77	BBSM397	Plasma	20	0.791	-0.016	0.079	0.086	-0.073
78	BBSM403	Plasma	23	1.658	0.292	0.022	0.035	0.113
79	BBSM409	Plasma	116	2.506	1.23	0.113	0.419	0.105
80	BBSM412	Plasma	84	2.703	1.75	0.029	0.379	0.073
81	BBSM417	Plasma	29	1.179	0.283	0.028	0.508	0.092
82	BBSM427	Plasma	139	0.748	0.38	0.017	0.144	0.09
83	LCTC451	Plasma	Unknown	1.634	0.338	0.057	0.15205	-0.048
84	LCTC457	Serum	Unknown	1.929	0.381	0.211	0.456	0.151
85	LCTC471	Plasma	Unknown	1.445	0.387	0.017	0.069	0.074

Table-S2. Neutralization activity measured as surrogate virus neutralization percentage (sVNT%) against the Wild Type, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant of concern were determined by C-Pass method in samples (serum/plasma) collected from 85 no-hospitalized COVID-19 convalescent subjects.

			sVNT% > 30%			
	ID	**Specimen**	**WILD TYPE**	**ALPHA**	**DELTA**	**OMICRON**
1	BBMC102	Serum	92	74	82	25
2	BBMC103	Serum	92	71	81	22
3	BBMC104	Serum	69	33	42	24
4	BBMC105	Serum	88	59	82	29
5	BBMC106	Serum	53	14	36	25
6	BBMC132	Serum	91	63	82	26
7	BBMC133	Serum	85	49	64	33
8	BBMC134	Serum	53	24	18	21
9	BBMC135	Serum	87	54	77	29
10	BBMC136	Serum	0	-8	22	8
11	BBMC137	Serum	70	30	43	18
12	HAM143	Serum	96	90	95	24
13	BBMC148	Serum	92	63	79	22
14	LMH151	Serum	94	78	88	25
15	BSCM152	Serum	72	52	45	24
16	LML153	Serum	93	70	89	2
17	BBSM155	Plasma	40	9	21	17
18	BBSM156	Plasma	77	35	54	9
19	BBSM157	Plasma	75	35	58	18
20	BBSM158	Plasma	94	73	85	24
21	BBSM159	Plasma	96	82	90	24
22	BBSM160	Plasma	47	6	26	17
23	BBSM161	Plasma	91	63	80	23
24	BBSM162	Plasma	84	50	59	20
25	BBSM163	Plasma	66	30	36	24
26	BBSM164	Plasma	78	47	49	6
27	BBSM165	Plasma	69	35	49	6
28	BBSM166	Plasma	55	24	23	16
29	BBSM167	Plasma	58	29	48	8
30	BBSM170	Plasma	89	61	65	5
31	BBSM171	Plasma	77	37	56	15
32	BBSM173	Plasma	93	71	80	17
33	BBSM176	Plasma	93	57	77	22
34	BBSM177	Plasma	79	45	58	14
35	BBSM178	Plasma	71	36	47	18
36	BBSM179	Plasma	71	39	41	10
37	BBSM180	Plasma	78	54	51	16
38	BBSM181	Plasma	65	30	35	10
39	BBSM182	Plasma	94	74	82	31
40	BBSM184	Plasma	65	23	46	14
41	LCTC192	Serum	53	11	20	12
42	BBMC193	Plasma	51.3	23	32	7
43	BBMC195	Plasma	96	84	86	28
44	BBSM199	Serum	54	14	29	13
45	BBSM201	Serum	96	-2	1	19
46	BBSM207	Plasma	86	23	63	13
47	BBSM209	Plasma	79	44	51	2
48	BBSM210	Plasma	92	65	76	15
49	BBSM214	Plasma	86	79	83	10
50	LCTC218	Serum	72	2	11	10

51	BBMC220	Plasma	89.9	83	89	20
52	BBSM229	Plasma	85	55	54	17
53	BBSM231	Plasma	90	66	72	21
54	UPR247	Serum	19	14	0	17
55	LV260	Plasma	81	58	61	13
56	LV261	Serum	97	91	94	24
57	LV262	Serum	86	59	72	21
58	BBSM275	Plasma	97	93	96	14
59	BBSM284	Plasma	91	70	67	18
60	BSSM288	Plasma	77	51	64	20
61	LCTC300	Serum	56	35	42	7
62	LCTC312	Plasma	83	44	70	15
63	BBSM318	Plasma	92	73	58	7
64	BBSM322	Plasma	94	66	79	2
65	LCTC367	Plasma	92	28	36	10
66	LCTC374	Serum	44	87	92	41
67	LCTC375	Serum	98	47	73	10
68	LCTC376	Serum	94	24	23	10
69	LCTC377	Serum	50	43	58	11
70	UPR381	Serum	76	32	33	13
71	UPR382	Plasma	72	58	62	12
72	LCTC384	Serum	87	48	54	10
73	BBSM386	Plasma	71.4	62	74	21
74	BBSM390	Plasma	92	66	75	15
75	BBSM391	Plasma	92	19	28	7
76	BBSM393	Plasma	65	23	37	13
77	BBSM397	Plasma	72	48	57	12
78	BBSM403	Plasma	88	74	82	18
79	BBSM409	Plasma	38.3	70	81	20
80	BBSM412	Plasma	92.6	19	34	21
81	BBSM417	Plasma	73	20	32	14
82	BBSM427	Plasma	51.8	42	70	21
83	LCTC451	Plasma	81	70	76	18
84	LCTC457	Serum	86	25	32	7
85	LCTC471	Plasma	31	58	76	15

Table-S3. Levels of IgG antibody subclasses to SARS-CoV-2 measured by in-house ELISAs and neutralizing percentages (sVNT%) measured by C-Pass surrogate virus neutralization test in serial samples collected from 12 COVID-19 convalescent subjects that received two doses of the mRNA vaccine (Pfizer-BioNTech or Moderna-1273).

ID & Vaccine	Sample	Time after 2nd Vaccine dose	Date	ELISA IgG >0.312	ELISA IgG1 >0.242	ELISA IgG2 >0.186	ELISA IgG3 >0.375	ELISA IgG4 >0.251	sVNT% WT	sVNT% Alpha	sVNT% Delta	sVNT% Omicron
	Pfizer-BioNTech											
JJJ367	1	Baseline	11/02/2020	2.578	1.510	0.090	0.509	0.313	92%	58%	77%	7%
	2	20 days	02/25/2021	2.467	3.522	0.068	0.158	0.612	97%	98%	97%	95%
	3	96 days	05/12/2021	2.004	1.028	0.013	0.021	0.523	97%	97%	96%	62%
IDG313	1	Baseline	01/12/2021	2.854	2.281	0.263	0.813	0.481	97%	83%	89%	10%
	2	16 days	03/04/2021	2.740	3.466	0.027	0.200	0.297	98%	98%	97%	98%
	3	134 days	06/30/2021	2.312	1.392	0.079	0.024	0.294	96%	98%	96%	95%
APR382	1	Baseline	01/14/2021	0.194	0.025	0.062	0.001	0.016	39%	23%	35%	10%
	2	20 days	03/05/2021	2.591	3.037	0.076	0.027	0.004	97%	98%	97%	91%
	3	83 days	05/07/2021	1.784	0.462	0.035	0.016	0.026	96%	98%	95%	45%
CRO384	1	Baseline	12/16/2020	1.037	0.162	0.129	0.287	0.232	69%	44%	52%	7%
	2	23 days	02/10/2021	2.848	3.524	0.235	0.134	0.022	98%	98%	97%	96%
	3	112 days	05/10/2021	1.456	0.075	0.016	0.047	0.012	97%	98%	96%	67%
NV471	1	Baseline	02/05/2021	0.692	0.145	0.095	0.099	0.015	24%	20%	19%	2%
	2	15 days	04/28/2021	2.028	1.651	0.694	0.198	0.010	98%	98%	97%	91%
	3	169 days	09/29/2021		0.105	0.024	0.040	0.016	97%	95%	95%	43%
CIR511	1	Baseline	01/27/2021	1.643	0.490	0.421	0.006	0.025	81%	55%	67%	9%
	2	26 days	03/17/2021	2.698	2.589	0.120	0.018	0.001	97%	98%	97%	75%
	3	83 days	05/13/2021	1.663	0.906	0.257	0.008	0.019	96%	97%	96%	52%
JAF512	1	Baseline	01/27/2021	0.539	0.004	0.058	0.022	0.701	46%	23%	43%	8%
	2	26 days	03/17/2021	2.693	2.815	0.026	0.104	0.786	89%	95%	93%	47%
	3	83 days	05/13/2021	1.826	0.610	0.029	0.031	0.652	96%	93%	94%	18%
HEV218	1	Baseline	11/2/2020	1.253	0.087	0.06	0.057	0.018	72%	29%	32%	-1%
	2	20 days	02/25/2021	2.575	3.536	0.036	0.405	0.000	97%	98%	97%	89%
	3	96 days	05/12/2021	1.988	1.211	0.033	0.316	0.007	97%	98%	96%	76%
	Moderna-1273											
CMV 294	1	Baseline	12/11/2020	1.535	0.010	0.005	0.038	0.012	90%	70%	72%	14%
	2	32 days	03/31/2021	2.399	1.180	0.099	0.006	0.154	98%	97%	96%	70%
	3	124 days	07/01/2021	1.724	0.148	0.125	0.086	0.197	96%	97%	96%	54%
RER 376	1	Baseline	12/18/2020	0.589	0.028	0.019	0.048	0.022	72%	34%	32%	1%
	2	18 days	03/12/2021	2.334	1.153	0.007	0.109	0.409	97%	98%	96%	88%
	3	74 days	05/07/2021	2.195	0.237	0.078	0.038	0.094	96%	98%	96%	63%
NS-455	1	Baseline	10/27/2020	0.415	0.028	0.024	0.215	0.005	33%	7%	9%	11%
	2	24 days	03/09/2021	2.261	0.426	0.104	0.155	0.050	97%	96%	96%	65%
	3	96 days	05/20/2021	1.697	0.034	0.166	0.024	0.059	96%	93%	94%	21%
EM-457	1	Baseline	10/30/2020	1.929	0.011	0.008	0.153	0.023	86%	62%	77%	10%
	2	23 days	06/14/2021	2.359	3.144	0.234	1.443	0.022	97%	98%	96%	98%
	3	117 days	09/16/2021	2.670	2.257	0.168	0.32	0.065	98%	98%	96%	95%

Table-S4. Levels of IgG antibody subclasses to SARS-CoV-2 measured by in-house ELISAs and neutralizing activity measured by C-Pass a surrogate virus neutralization assay (sVNT%) in serial samples collected from 14 subjects without previous SARS-CoV-2 infection that received multiple mRNA vaccinations (Pfizer-BioNTech or Moderna-mRNA-1273).

ID	Sample	Time Point	Sample Date	ELISA IgG >0.312	ELISA IgG1 >0.242	ELISA IgG2 >0.186	ELISA IgG3 >0.375	ELISA IgG4 >0.251	sVNT% WT	sVNT% Alpha	sVNT% Delta	sVNT% Omicron
Cohort-3a: Serial samples from no-previous SARS-CoV-2 infected subjects that received multiple mRNA vaccinations (Pfizer-BioNTech)												
NM-249	1	Baseline	12/21/2020	0.007	0.064	0.019	0.017	0.059	19%	-3%	-5%	7%
	2	35 days 2nd dose	02/24/2021	2.217	3.046	0.077	2.039	0.059	97%	90%	95%	33%
	3	31 days 3rd dose	11/09/2021		0.890	0.675	0.243	3.870	98%	97%	96%	74%
	4	180 days 3rd dose	05/03/2022		1.191	1.829	0.158	3.920	98%	97%	96%	97%
	5	30 days Bivalent	10/11/2022	2.627	1.392	2.588	0.108	3.930	97%	96%	97%	98%
	6	180 days Bivalent	03/15/2023	2.171	0.314	0.463	0.011	3.510	97%	97%	97%	95%
CS-116	1	Baseline	12/21/2020	0.057	0.011	0.018	0.006	0.011	-1%	-4%	0%	7%
	2	21 days 2nd dose	03/04/2021	2.635	3.255	0.163	3.989	0.019	97%	95%	95%	66%
	3	31 days 3rd dose	01/13/2022		0.974	0.227	0.063	3.897	98%	98%	96%	94%
	4	180 days 3rd dose	10/11/2022	2.572	0.742	0.234	0.084	3.906	97%	97%	97%	96%
	5	30 days Bivalent	11/30/2022	2.440	1.996	0.672	0.103	3.893	96%	97%	97%	98%
	6	180 days Bivalent	04/11/2023	2.004	0.268	0.105	0.010	3.606	97%	98%	97%	97%
LAC-117	1	Baseline	8/10/2020	0.082	0.020	0.053	0.028	0.041	2%	-1%	-2%	8%
	2	19 days 2nd dose	03/04/2021	2.665	3.409	0.079	3.728	0.110	97%	92%	95%	46%
	3	31 days 3rd dose	11/09/2021		1.740	0.097	2.078	2.845	98%	97%	96%	97%
	4	330 days 3rd dose	10/11/2022	1.501	0.226	0.016	0.112	2.703	97%	96%	96%	39%
	5	30 days Bivalent	11/10/2022	2.185	1.641	0.004	0.084	3.905	97%	95%	98%	97%
	6	180 days Bivalent	04/13/2023	1.684	0.096	0.022	0.026	2.440	97%	97%	98%	88%
AEM-254	1	Baseline	01/13/2021	0.009	0.099	0.009	0.017	0.018	18%	-9%	1%	2%
	2	19 days 2nd dose	03/04/2021	2.604	3.331	0.030	2.133	0.063	96%	92%	95%	39%
	3	43 days 3rd dose	01/12/2022		1.809	0.433	0.115	3.850	98%	98%	96%	92%
	4	420 days 3rd dose	03/15/2023	1.324	0.104	0.005	0.012	3.767	96%	94%	95%	-1%
	5	30 days Bivalent	05/25/2023	2.182	1.432	1.648	0.136	3.801	98%	98%	96%	98%
	6	90 days Bivalent	08/10/2023	2.052	0.287	0.631	0.009	3.474	98%	98%	96%	98%
Cohort 3b: Single sample collected after the third Pfizer-BioNTech dose from no-previously infected individuals.												
LMM	1	351 days bivalent	09/13/2023		1.610	0.199	0.026	3.678	98	98	96	98
RRN	1	635 days 3rd dose	10/23/2023		0.717	0.265	0.275	3.905	98	98	96	97
AAR	1	723 days 3rd dose	10/23/2023		0.146	0.230	0.098	0.510	98	98	96	95
COM	1	633 days 3rd dose	10/23/2023		0.738	0.236	0.256	2.709	98	98	96	98
AEC	1	630 days 3rd dose	10/23/2023		0.171	3.153	0.101	3.870	98	98	96	98
JMJ	1	715 days 3rd dose	10/23/2023		0.150	0.085	0.011	2.820	98	98	96	95
MFG	1	715 days 3rd dose	10/23/2023		0.286	0.482	0.006	3.975	98	98	96	98
JGR	1	485 days 3rd dose	08/03/2023		0.256	0.764	0.149	3.945	98	98	96	97
Cohort-4: No-previous SARS-CoV-2 infection, with inflammatory bowel disease (IBD) that received three mRNA vaccine doses (Pfizer-BioNTech)												
006-V1	1	Baseline	04/14/2021	0.1272	0.005	0.021	0.020	0.054	-11%	14%	5%	7%
	2	30 days 2nd dose	06/09/2021	2.3997	1.710	0.123	0.236	0.026	97%	97%	99%	65%
	3	60 days 3rd dose	03/04/2022	2.7545	2.341	0.927	0.097	3.475	98%	97%	96%	97%
	4	180 days 3rd dose	07/05/2022	2.4298	0.312	0.096	0.019	3.524	98%	97%	96%	92%
013-V1	1	Baseline	04/15/2021	0.0011	0.023	0.097	0.004	0.008	-20%	4%	2%	10%
	2	15 days 2nd dose	05/28/2021	1.6659	0.150	0.103	0.369	0.005	88%	60%	57%	12%
	3	60 days 3rd dose	12/09/2021	2.3597	0.315	0.134	0.274	0.008	98%	93%	95%	23%
	4	180 days 3rd dose	04/06/2022		0.020	0.207	0.11	0.007	91%	74%	86%	0%
014-V1	1	Baseline	04/16/2021	0.0126	0.008	0.034	0.008	0.009	-5%	-7%	-1%	2%
	2	15 days 2nd dose	05/28/2021	2.2356	1.278	0.006	0.633	0.015	97%	92%	96%	42%
	3	60 days 3rd dose	01/13/2022	2.0671	0.282	0.011	0.094	1.683	98%	97%	96%	50%
	4	180 days 3rd dose	05/13/2022		0.115	0.016	0.015	0.560	96%	93%	94%	10%
016-V1	1	Baseline	04/16/2021	0.0075	0.005	0.096	0.003	0.004	-15%	-3%	-6%	6%
	2	15 days 2nd dose	05/26/2021	2.3267	2.482	0.081	0.705	0.018	97%	97%	98%	59%
	3	60 days 3rd dose	03/01/2022	2.6183	2.083	0.331	0.039	3.588	98%	98%	96%	98%
	4	180 days 3rd dose	07/05/2022	2.1966	0.205	0.017	0.014	1.931	98%	98%	96%	82%

019-V1	1	Baseline	04/28/2021	0.0327	0.020	0.015	0.001	0.006	2%	1%	-2%	1%
	2	15 days 2nd dose	06/09/2021	2.2864	0.929	0.172	0.670	0.015	95%	90%	80%	23%
	3	60 days 3rd dose	03/28/2022	2.7314	2.090	0.587	0.030	3.697	98%	98%	96%	98%
	4	180 days 3rd dose	07/22/2022	2.4546	0.443	0.113	0.005	2.298	98%	98%	96%	98%

(A)



(B)

Reproducibility of in-house IgG ELISA

			Repeatability (Within-Run)		Within-Laboratory [a]	
Sample	**N**	**Mean A_{492}**	**SD**	**% CV**	**SD**	**% CV**
NC	30	0.022	0.021	N/A[b]	0.0026	N/A[b]
HPC	30	2.476	0.211	8.52	0.219	8.84
NS-1	6	0.049	0.011	N/A[b]	0.014	N/A[b]
NS-2	6	0.043	0.016	N/A[b]	0.032	N/A[b]
NS-3	6	0.042	0.024	N/A[b]	0.035	N/A[b]
NS-4	6	0.062	0.005	N/A[b]	0.006	N/A[b]
PS-1	6	2.085	0.011	0.527	0.075	3.59
PS-2	6	2.37	0.05	2.109	0.012	0.506
PS-3	6	2.235	0.015	0.671	0.15	6.71
PS-4	6	3.17	0.057	1.79	0.28	8.83

[a] Includes repeatability (Within-run), between-run and between-day variability.
[b] Not applicable
HPC: High positive control, NS: Negative serum, PC: Positive serum
NC: Negative control

Figure-S1. Deming analysis for serum-plasma equivalence and reproducibility of the in house IgG-ELISA. **(A)** Deming regression analysis was performed on paired 10 plasma and serum specimens collected from the same individual to demonstrate the equivalence in the assays results for both specimens. (B) Intra-assay and inter-assay reproducibility of the in-house IgG ELISA was determined from three independent assays and 30 repeats of controls or negative and positive samples.